Quick Answer
FATE THERAPEUTICS INC reported Total Revenue of $6.65 million for the year ending 2025.
- FATE THERAPEUTICS INC showed a decrease of -51.2% in Total Revenue from 2024 to 2025.
- This data is from FATE THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $1.03 million | Q2 2017: $1.03 million | Q3 2017: $1.03 million | Q4 2017: $1.03 million | Q1 2018: $1.03 million | Q2 2018: $1.03 million | Q3 2018: $1.03 million | Q4 2018: $1.66 million | Q1 2019: $2.63 million | Q2 2019: $2.82 million | Q3 2019: $2.43 million | Q4 2019: $2.80 million | Q1 2020: $2.52 million | Q2 2020: $5.47 million | Q3 2020: $7.56 million | Q1 2021: $11.14 million | Q2 2021: $13.41 million | Q3 2021: $14.23 million | Q1 2022: $18.41 million | Q2 2022: $18.55 million | Q3 2022: $14.98 million | Q1 2023: $58.98 million | Q2 2023: $933.0 thousand | Q3 2023: $1.94 million | Q1 2024: $1.93 million | Q2 2024: $6.77 million | Q3 2024: $3.07 million | Q1 2025: $1.63 million | Q2 2025: $1.91 million | Q3 2025: $1.74 million.
- Over the full 10 years of available data (2016 to 2025), FATE THERAPEUTICS INC's Total Revenue has grown by 51.0%.
- Historical annual values: Fiscal year 2025: $6.65 million | Fiscal year 2024: $13.63 million | Fiscal year 2023: $63.53 million | Fiscal year 2022: $96.30 million | Fiscal year 2021: $55.85 million | Fiscal year 2020: $31.43 million | Fiscal year 2019: $10.68 million | Fiscal year 2018: $4.74 million | Fiscal year 2017: $4.11 million | Fiscal year 2016: $4.40 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: